12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Indacaterol/glycopyrronium bromide: Phase III data

Top-line data from the double-blind, international Phase III SPARK trial in 2,224 patients with severe to very severe COPD showed that once-daily QVA149 met the primary endpoint of reducing the rate of moderate to severe COPD exacerbations from baseline to week 64 vs. once-daily 50 µg NVA237 (p=0.038). QVA149 missed the secondary endpoint of reducing the rate of moderate to severe COPD exacerbations vs. open-label 18 µg tiotropium (p=0.096), but did significantly reduce the overall rate of all exacerbations vs. both NVA237 (p=0.001) and tiotropium (p=0.002). The adverse event profile of...

Read the full 433 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >